NEWSROOM
Press Releases by Agendia
News
Press Releases
Breast Cancer is the Most Feared Cancer Among Women in Germany, Although Less than Half are Aware of the Benefits of Genomic Testing
KANTAR survey: Only 40% of breast cancer patients know the benefits of genomic testing IRVINE, CA and AMSTERDAM, 9 October 2017 – Breast cancer is the most feared type of cancer among women in Germany, Read More
Breast Cancer – Let’s Make It Personal: Agendia Supports Breast Cancer Awareness Month with International Program of Activities
Flash Mob for Breast Cancer Empowerment, in partnership with the Tigerlily Foundation, takes place at the Lincoln Memorial in Washington, DC on Saturday 14 October International events including support of Susan G. Komen Race for Read More
10-Year Prospective Outcome Data and MINDACT Sub-Study Presented at ESMO Congress Demonstrate Prognostic Value of MammaPrint in Personalizing Early-Stage Breast Cancer Treatment
First time 10-year prospective outcome data confirms clinical utility of MammaPrint for lymph node-negative and lymph node-positive patients MINDACT sub-study shows that even tumors less than 1cm in size can be aggressive with 24% reclassified Read More
Agendia’s MammaPrint Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data
ASCO® recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions on withholding chemotherapy ASCO recommends MammaPrint as currently the only genomic test to be used to guide treatment decisions for Read More
Agendia’s MammaPrint recommended by the 2017 St. Gallen International Breast Cancer Guidelines in significant update
IRVINE, CA and AMSTERDAM – 6 July 2017 - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics announces that the 15th St. Gallen International Breast Cancer Guidelines recently published in Annals Read More
MammaPrint Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment
Retrospective analysis of patient samples from the prospective, randomized Stockholm Tamoxifen Trial demonstrates clinical utility of MammaPrint in identifying breast cancer patients with exceedingly low likelihood for late recurrence at 20-years MammaPrint Late Recurrence (20yr) Read More
Three New Studies Presented at ASCO Annual Meeting Demonstrate Benefits of MammaPrint in Aiding Individualized Treatment Management for Early-Stage Breast Cancer Patients
A multi-center trial demonstrated that MammaPrint identified 30% more low risk patients than the 21-gene test. MammaPrint Low Risk patients had an excellent 98.9% 5-year metastasis free survival Data from the I-SPY 2 trial reported Read More